Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Unraveling Tumorigenicity in iPSC-Derived Immune Cells: The Impact of Chromosomal Abnormalities and Proliferative Intermediates

Manali Begur, Takayoshi Yamauchi, Hidehito Saito, Takaaki Oba, Ryutaro Kajihara, Leighton Stein, Mark Hoenerhoff, Fumito Ito

Blood (2023) 142 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2023-186852

Published: 2023

Journal Articles

Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.

Pushpankur Ghoshal, PhD, Kasyapa Chitta, Ph.D., Slavoljub Vujcic, Jacquelyne Gaddy, Kiersten M. Miles, Leighton Stein, Taimur Sher, MD, Kelvin P. Lee, MD, Asher A. Chanan-Khan, MD

Blood (2009) 114 (22): 2832.

https://doi.org/10.1182/blood.V114.22.2832.2832

Published: 2009

Journal Articles

At-101 Induces Apoptosis Waldenström Macroglobulinemia Cells Resistant to Bortezomib.

Kasyapa Chitta, Ph.D., Kiersten M. Miles, Pushpankur Ghoshal, PhD, Leighton Stein, Morton Coleman, MD, Richard R Furman, MD, Hofmeister Craig, MD, Suzanne Hayman, Kelvin P. Lee, MD, Asher Alban Chanan-Khan

Blood (2009) 114 (22): 2861.

https://doi.org/10.1182/blood.V114.22.2861.2861

Published: 2009

Journal Articles

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

Kasyapa Chitta, Ph.D., Jean-Gabriel Coignet, Sakina Sojar, Pushpankur Ghoshal, PhD, Kiersten M. Miles, Leighton Stein, Morton Coleman, MD, Richard R. Furman, MD, Craig Hofmeister, MD, Suzanne Hayman, MD, Kelvin P. Lee, MD, Asher A. Chanan-Khan, MD

Blood (2009) 114 (22): 4919.

https://doi.org/10.1182/blood.V114.22.4919.4919

Published: 2009

Journal Articles

Validating Molecular Targets of Thalidomide in CLL: Net Effect of Increased Apoptosis through the Intrinsic Pathway and down Regulation of NF-kB Signaling- Validation Using Gene Expression Profile from the Phase I/II Clinical Trial of Thalidomide and Fludarabine.

Asher Alban Chanan-Khan, MD, Swaminathan Padmanabhan, MD, Leighton Stein, Jennifer Panzarella, Kena C. Miller, Leslie Hawthorne, Ph.D

Blood (2005) 106 (11): 5043.

https://doi.org/10.1182/blood.V106.11.5043.5043

Published: 2005

NARROW

Unraveling Tumorigenicity in iPSC-Derived Immune Cells: The Impact of Chromosomal Abnormalities and Proliferative Intermediates

Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.

At-101 Induces Apoptosis Waldenström Macroglobulinemia Cells Resistant to Bortezomib.

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

Validating Molecular Targets of Thalidomide in CLL: Net Effect of Increased Apoptosis through the Intrinsic Pathway and down Regulation of NF-kB Signaling- Validation Using Gene Expression Profile from the Phase I/II Clinical Trial of Thalidomide and Fludarabine.

Email alerts

ASH Publications

American Society of Hematology

Unraveling Tumorigenicity in iPSC-Derived Immune Cells: The Impact of Chromosomal Abnormalities and Proliferative Intermediates

Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.

At-101 Induces Apoptosis Waldenström Macroglobulinemia Cells Resistant to Bortezomib.

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

Validating Molecular Targets of Thalidomide in CLL: Net Effect of Increased Apoptosis through the Intrinsic Pathway and down Regulation of NF-kB Signaling- Validation Using Gene Expression Profile from the Phase I/II Clinical Trial of Thalidomide and Fludarabine.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only